(Cisplatin + vinblastine sulphate) is under clinical development by Intensity Therapeutics and currently in Phase III for Myxoid Liposarcoma. According to GlobalData, Phase III drugs for Myxoid Liposarcoma does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the (Cisplatin + vinblastine sulphate) LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Cisplatin + vinblastine sulphate) overview
Cisplatin in a fixed dose combination with vinblastine sulfate (INT-2306) is under development for the treatment of solid tumors, melanoma, lymphoma, head and neck, liver, chordoma, metastatic colorectal cancer, cutaneous squamous cell carcinoma, lung, metastatic pancreatic, ovarian, thyroid, colon, metastatic hepatocellular carcinoma, triple negative breast cancer, breast cancer, soft tissue sarcomas, liposarcoma (dedifferentiated, myxoid, round cell or pleomorphic), leiomyosarcoma (non-uterine), undifferentiated pleomorphic sarcoma, glioblastoma multiforme and bile duct cancer. The drug candidate is administered intratumorally and intravenously. The drug candidate is developed based on intratumoral amphiphilic solutions technology and DfuseRx technology platform.
Intensity Therapeutics overview
Intensity Therapeutics is a clinical-stage biotechnology company that focuses on human clinical testing to treat refractory solid tumor cancers. The company is headquartered in Fairfield, Connecticut, the US.
For a complete picture of (Cisplatin + vinblastine sulphate)’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
